[Form 4] Corcept Therapeutics Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Insider Trade Summary
Net Seller: 35,007 shares ($2,373,237)
Net Sell
10 txns
Insider
Maduck Sean
Role
See Remarks
Sold
35,007 shs ($2.37M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 35,007 | $0.00 | -- |
| Exercise | Common Stock | 35,007 | $5.05 | $177K |
| Sale | Common Stock | 27,865 | $67.5334 | $1.88M |
| Sale | Common Stock | 5,428 | $68.5247 | $372K |
| Sale | Common Stock | 1,714 | $69.7008 | $119K |
| Gift | Common Stock | 40,000 | $0.00 | -- |
| Other | Common Stock | 40,000 | $0.00 | -- |
| Gift | Common Stock | 10,024 | $0.00 | -- |
| Other | Common Stock | 10,024 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 21,986 shares (Direct);
Common Stock — 42,688 shares (Direct);
Common Stock — 59,717 shares (Indirect, See Footnote)
Footnotes (1)
- Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Transfer of shares without consideration to the SNM 2025 Grantor Retained Annuity Trust. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $67.17 to $68.10 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $68.17 to $69.13 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.48 to $69.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Fully exercisable.
